返回 
加入收藏
我国非免费抗HIV药品及用药方案的价格与可负担性分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 我国非免费抗HIV药品及用药方案的价格与可负担性分析 |
| TITLE： | Price and affordability analysis of non-free anti-HIV drugs and therapeutic regimen in China |
| 摘要： | 目的 为促进我国艾滋病用药的经济性提供建议和参考。方法根据《中国艾滋病诊疗指南（2021版）》和《国家免费艾滋病抗病毒药物治疗手册（第4版）》筛选非免费抗人类免疫缺陷病毒（HIV）药品及用药方案，搜集国内外药品价格数据，通过标准调查法，使用中位价格比值（MPR）法和药品可负担性研究法分析非免费抗HIV药品及用药方案的价格和可负担性。结果共筛选得到18种非免费抗HIV药品（以药品名称计），其中5种药品仅有国产药，11种仅有进口药，2种兼有国产药和进口药，8种被列入《基本医疗保险目录（2021版）》。18种药品的MPR中位值为0.504，在医保报销前可负担性小于1的药品占药品总数的55%，医保报销后这一数据提升为75%。10种单片复方制剂报销后的可负担性中位值为0.625，其中被指南推荐可单独使用的4种单片复方制剂的可负担性均小于1。用药方案中的推荐方案和替代方案在医保报销前后以及报销后两方案之间的可负担性差异均无统计学意义（P＞0.05）。结论我国非免费抗HIV药品的单品可负担性良好，联合用药方案的可负担性差；单片复方制剂相较传统治疗方案的可负担性优势显著。政府和企业应以研发创新药品、加强药品价格管制为重点，建立健全针对HIV/艾滋病群体的非免费药品保障体系，使其可选择药品更多样、用药更经济。 |
| ABSTRACT： | OBJECTIVE To provide suggestions and references for promoting the economic efficiency of anti -AIDS drug use in China .METHODS According to the Chinese Guidelines for the Diagnosis and Treatment of AIDS （2021 Edition）and the National Free HIV Antiretroviral Drug Treatment Manual （4th Edition ），non-free anti -HIV drugs and therapeutic regimens were screened；the data on domestic and foreign drug prices were collected ，and the price and affordability of non -free anti -HIV drugs and drug regimens were analyzed with the median price ratio （MPR）method and drug affordability study method by standard survey method . RESULTS A total of 18 non-free anti -HIV drugs （based on drug names ）were screened ，of which 5 drugs were only domestically produced ，11 were only imported ，and 2 were both domestic and imported drugs ；eight types were listed in the Basic Medical Insurance Catalogue （2021 Edition）. The median MPR for 18 drugs was 0.504，and drugs with affordability of less than 1 accounted for 55% of the total number of drugs before medicare reimbursement ，and this figure increased to 75% after medicare reimbursement . The median affordability after reimbursement of 10 single-tablet combinations was 0.625，of which the affordability of the four single -tablet combinations recommended by the guidelines for use alone was less than 1. There was no statistically significant difference in the affordability of two regimens before and after medicare reimbursement and between recommended regimens and alternatives after reimbursement （P＞0.05）. CONCLUSIONS The affordability of single non -free anti - HIV drugs in China is good ，but the affordability of combination drugs is poor . The affordability advantages of single -tablet combination formulations over conventional therapeutic regimens are significant . The government and enterprises should focus on the research and development of innovative drugs and strengthen drug price control ，and establish and improve the non -free drug protection system for HIV/AIDS groups ，so that they can choose more drugs and use drugs more economically . |
| 期刊： | 2022年第33卷第21期 |
| 作者： | 王旋辉，宫春博 |
| AUTHORS： | WANG Xuanhui，GONG Chunbo |
| 关键字： | 艾滋病；抗人类免疫缺陷病毒；药品价格；可负担性 |
| KEYWORDS： | AIDS；HIV；drug price ；affordability |
| 阅读数： | 190 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
